Hyperfine (NASDAQ:HYPR) Announces Quarterly Earnings Results, Hits Expectations

Hyperfine (NASDAQ:HYPR) issued its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09), FiscalAI reports. The company had revenue of $3.90 million during the quarter, compared to the consensus estimate of $4.13 million. Hyperfine had a negative return on equity of 99.81% and a negative net margin of 210.75%.

Here are the key takeaways from Hyperfine’s conference call:

• Revenue rose 45% year over year to $3.9 million in Q2, while system sales increased 50% to 12 units; first-half revenue reached $7.8 million.
• Gross margin remained above 50% for the fourth consecutive quarter at 50.7%, while first-half cash burn improved approximately 9% year over year to $16.6 million.
• Management reiterated 2026 revenue guidance of $20 million to $22 million, gross margin of 50% to 55%, cash burn of $26 million to $28 million, and cash runway extending into 2028.
• Growth is broadening across hospitals and IDNs, neurology offices, and international markets; the company cited initial large-IDN adoption, more than a dozen office placements, and first European Model 2 sales.
• Hyperfine remains loss-making, reporting a $9.3 million quarterly net loss, and its stronger cash position partly reflects $10.6 million raised through its ATM program, which may create shareholder dilution.

Hyperfine Trading Down 2.7%

Hyperfine stock traded down $0.03 during mid-day trading on Friday, hitting $0.95. The company’s stock had a trading volume of 904,666 shares, compared to its average volume of 732,139. The company has a 50 day moving average of $1.23 and a 200-day moving average of $1.25. The stock has a market cap of $94.80 million, a PE ratio of -2.51 and a beta of 1.42. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.90 and a current ratio of 5.52. Hyperfine has a one year low of $0.85 and a one year high of $2.22.

Institutional Trading of Hyperfine

Several institutional investors and hedge funds have recently made changes to their positions in HYPR. EP Wealth Advisors LLC bought a new position in shares of Hyperfine in the fourth quarter worth about $34,000. Millennium Management LLC purchased a new stake in Hyperfine in the 4th quarter valued at about $55,000. Cerity Partners LLC purchased a new stake in Hyperfine in the 4th quarter valued at about $59,000. XTX Topco Ltd grew its stake in Hyperfine by 47.9% in the 4th quarter. XTX Topco Ltd now owns 80,735 shares of the company’s stock worth $79,000 after acquiring an additional 26,165 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in Hyperfine by 50.2% in the 4th quarter. Bridgeway Capital Management LLC now owns 119,700 shares of the company’s stock worth $117,000 after acquiring an additional 40,000 shares in the last quarter. 15.03% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HYPR. Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperfine in a research note on Friday, July 17th. B. Riley Financial reaffirmed a “buy” rating on shares of Hyperfine in a research note on Wednesday, May 13th. Finally, BTIG Research began coverage on shares of Hyperfine in a report on Wednesday, April 29th. They set a “buy” rating and a $2.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $1.78.

Hyperfine Company Profile

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.